[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100619437":3},{"organization":4,"outcomesModule":7,"designInfo":18,"detailedDescription":11,"studyPopulation":21,"armGroups":11,"interventions":22,"overallOfficials":11,"centralContacts":11,"locations":27,"responsibleParty":48,"collaborators":11,"id":52,"slug":11,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":11,"eligibilityCriteria":57,"healthyVolunteers":53,"sex":58,"minAge":59,"maxAge":11,"enrollmentInfo":60,"targetDuration":11,"studyType":63,"phases":11,"briefSummary":64,"conditions":65,"keywords":11,"overallStatus":30,"whyStopped":11,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},{"fullName":5,"class":6},"General Hospital of Shenyang Military Region","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"Absolute reduction in Low-Density Lipoprotein Cholesterol",null,"7±1 days",[14,16],{"measure":15,"description":11,"timeFrame":12},"Absolute and relative reductions in other lipid parameters (Total Cholesterol, Triglyceride, High-Density Lipoprotein Cholesterol, Lipoprotein a)",{"measure":17,"description":11,"timeFrame":12},"Changes in high-sensitivity C-reactive protein",{"allocation":11,"interventionModel":11,"interventionModelDescription":11,"primaryPurpose":11,"observationalModel":19,"timePerspective":20,"maskingInfo":11},"COHORT","PROSPECTIVE","patients with ischemic stroke (within 14 days of onset) confirmed by cranial CT\u002FMRI, or imaging-confirmed intracranial\u002Fextracranial atherosclerotic stenosis (stenosis rate ≥ 50%);",[23],{"type":24,"name":25,"description":26,"armGroupLabels":11,"otherNames":11},"DRUG","statin","Atorvastatin 40-80mg\u002Fday, Rosuvastatin 20mg\u002Fday",[28],{"facility":29,"status":30,"city":31,"state":32,"zip":33,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"Lu Wang","RECRUITING","Shenyang","Liaoning","110840","China","CN",{"type":37,"coordinates":38},"Point",[39,40],123.43278,41.79222,{"lat":40,"lon":39},[43],{"name":44,"role":45,"phone":46,"phoneExt":11,"email":47},"Yu Cui","CONTACT","862428897491","cuiyu.spu@hotmail.com",{"type":49,"investigatorFullName":50,"investigatorTitle":51,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","Hui-Sheng Chen","Director","100619437",false,"NCT07344610","Effects of Short-term Intensive Statin Therapy on Lipid Levels","Effects of Short-term Intensive Statin Therapy on Lipid Levels in Patients With Ischemic Stroke or Large Artery Atherosclerosis: A Prospective Observational Study","Inclusion Criteria:\n\n* Age ≥ 18 years;\n* Diagnosis of ischemic stroke (within 14 days of onset) confirmed by cranial CT\u002FMRI; or imaging-confirmed intracranial\u002Fextracranial atherosclerotic stenosis (stenosis rate ≥ 50%);\n* Intensive statin therapy (e.g., atorvastatin 40-80 mg\u002Fday or rosuvastatin 20 mg\u002Fday) initiated within 24 hours of admission, with a planned continuous application for at least one week;\n* Signed informed consent form.\n\nExclusion Criteria:\n\n* Use of statin therapy within 1 week prior to admission;\n* Receiving other lipid-lowering treatments;\n* Presence of other serious comorbidities (e.g., malignant tumors, end-stage heart failure) with an expected survival of \\\u003C1 year;\n* Pregnant or lactating women;\n* Participation in other drug clinical trials within 3 months;\n* Other conditions deemed unsuitable by the investigator.","ALL","18 Years",{"count":61,"type":62},800,"ESTIMATED","OBSERVATIONAL","Acute cerebral infarction (ACI), often linked to arterial stenosis, is a major cause of death and disability. Statins are cornerstone therapies for secondary prevention, effectively lowering LDL-C and stabilizing plaques. However, patient response to intensive statin therapy varies significantly. This prospective study aims to analyze the short-term lipid-lowering effects and influencing factors of such therapy in ACI patients with stenosis, to guide personalized treatment and improve outcomes.",[66],"Ischemic Stroke","2026-01-07",{"date":69,"type":70},"2026-01-15","ACTUAL",{"date":72,"type":70},"2026-01-08",{"date":74,"type":62},"2026-12-30",{"name":5,"class":6},1]